Levemir Innolet (Insulin Detemir)

Insulin detemir binds to insulin receptors on muscle, fat and liver cells, activating pathways that increase glucose uptake and suppress hepatic glucose production. Its fatty‑acid side chain allows reversible albumin binding, extending its duration of action and creating a flat, basal insulin profile.

The dose of Levemir Innolet is individualized and set by a qualified prescriber based on factors such as the patient’s type of diabetes, current blood‑glucose patterns, body weight, renal and hepatic function, and concurrent medications. Patients should follow the dosing instructions provided by their healthcare professional.

Insulin is generally considered the preferred treatment for diabetes during pregnancy and lactation because it does not cross the placenta in harmful amounts. However, specific safety data for insulin detemir are limited, so clinicians weigh the benefits against potential risks and monitor both mother and infant closely.

To order Levemir Innolet, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and necessary import documentation.

Levemir Innolet (insulin detemir) offers a predictable, once‑ or twice‑daily dosing schedule with a relatively flat 24‑hour profile, similar to other long‑acting analogs such as glargine. Compared with some alternatives, detemir has a lower risk of nocturnal hypoglycemia but may require higher unit doses to achieve the same glucose‑lowering effect.

Levemir Innolet should be stored in a refrigerator at 2‑8 °C (36‑46 °F). Keep the vial in its original carton, protect it from light, and avoid freezing. Once in use, the solution may be kept at controlled room temperature (up to 30 °C) for up to 28 days, but should not be shaken vigorously.

Levemir Innolet is administered by subcutaneous injection, typically into the abdomen, thigh or upper arm. The injection site should be rotated to reduce lipodystrophy. Dosing frequency (once or twice daily) is determined by the prescriber based on individual glycemic targets and patient response.

The most serious risks include severe hypoglycemia, which can cause seizures or loss of consciousness, and allergic reactions ranging from rash to anaphylaxis. Patients should be educated to recognize early signs of low blood glucose and to seek immediate medical attention for any signs of a severe allergic response.

Levemir Innolet should not be used by individuals with a known hypersensitivity to insulin detemir or any of the excipients in the formulation. It is also contraindicated in patients experiencing hypoglycemia until the condition is corrected, and caution is advised in those with severe renal or hepatic impairment.